Back to Stocks

BDTX

Black Diamond Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Black Diamond Therapeutics is evolving into a lean, clinically focused oncology platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of efficiency, Black Diamond Therapeutics remains a cash-burning entity with no recurring revenue. The company reported a net loss of $9.0 million in the first quarter of 2026, and its operating cash flow was negative $10.2 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every BDTX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing paints a picture of a biotechnology company at a critical inflection point. Black Diamond has successfully extended its runway and trimmed its operational overhead, shifting from a broad discovery engine to a focused clinical executor. The strategic out-licensing of BDTX-4933 to Servier has provided the necessary financial cushion to pursue silevertinib without immediate pressure for capital markets access. However, the tension for investors lies in the gap between operational leaness and clinical certainty. While the balance sheet is stabilized for the near term, the company's valuation remains tethered to the success of silevertinib's CNS penetration and the subsequent results of the GBM and NSCLC trials. The upcoming ASCO presentation serves as the immediate catalyst that will likely determine if the market views BDTX as a de-risked oncology leader or a speculative bet on a narrow set of mutations.

Selected Quarter

Core Takeaway

The company has shifted to a leaner operating model with a significant cash cushion, but remains exposed to binary clinical trial outcomes.

Investor Lens

The trade-off is between the current financial stability (cash through 2028) and the high binary risk of the upcoming ASCO data and GBM trial.

Watch Next

Updated efficacy and survival metrics for silevertinib at the ASCO Annual Meeting (May 29 - June 2, 2026).

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.43Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%
bullishMay 7

Total operating expenses decreased 27% year-over-year due to workforce efficiencies and program consolidation.

margin expansion
60%
neutralMay 7

Utilized ATM program to raise approximately $25 million in gross proceeds.

capital raise
40%
bullishMay 7

Strategic partnership with Servier provided $70M upfront and potential for $710M in milestones.

acquisition
70%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing paints a picture of a biotechnology company at a critical inflection point. Black Diamond has successfully extended its runway and trimmed its operational overhead, shifting from a broad discovery engine to a focused clinical executor. The strategic out-licensing of BDTX-4933 to Servier has provided the necessary financial cushion to pursue silevertinib without immediate pressure for capital markets access. However, the tension for investors lies in the gap between operational leaness and clinical certainty. While the balance sheet is stabilized for the near term, the company's valuation remains tethered to the success of silevertinib's CNS penetration and the subsequent results of the GBM and NSCLC trials. The upcoming ASCO presentation serves as the immediate catalyst that will likely determine if the market views BDTX as a de-risked oncology leader or a speculative bet on a narrow set of mutations.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.